Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

VIVEK SUBBIAH

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1174726384
CMS profile
189527
Location
HOUSTON, TX

General Payments · PY2018–2024

$146,949.30

  • Reported across 102 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$19,081.26

35 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $1,848.59 3
PY2019 $19,301.29 18
PY2020 $18,821.97 5
PY2021 $19,902.50 10
PY2022 $43,303.88 11
PY2023 $24,689.81 20
PY2024 $19,081.26 35

Payment records · PY2024 (35)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $53.20 05/30/2024 Food and Beverage Undisputed 01/23/2026 1106177843 CMS
AstraZeneca Pharmaceuticals LP $1,370.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 1105704540 CMS
AstraZeneca Pharmaceuticals LP $32.61 04/26/2024 Food and Beverage Undisputed 01/23/2026 1104384935 CMS
AstraZeneca Pharmaceuticals LP $19.31 08/02/2024 Food and Beverage Undisputed 01/23/2026 1104480908 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.20 11/14/2024 Food and Beverage Undisputed 01/23/2026 1117903644 CMS
Daiichi Sankyo Inc. $17.61 03/28/2024 Food and Beverage Undisputed 01/23/2026 1089487576 CMS
Daiichi Sankyo Inc. $27.69 12/12/2024 Food and Beverage Undisputed 01/23/2026 1089487574 CMS
Deciphera Pharmaceuticals Inc. $22.34 03/18/2024 Food and Beverage Undisputed 01/23/2026 1145875531 CMS
E.R. Squibb & Sons, L.L.C. $18.78 04/25/2024 Food and Beverage Undisputed 01/23/2026 1101245410 CMS
E.R. Squibb & Sons, L.L.C. $18.12 12/19/2024 Food and Beverage Undisputed 01/23/2026 1101245472 CMS
Eli Lilly and Company $359.00 01/18/2024 Travel and Lodging Undisputed 01/23/2026 1135440867 CMS
Eli Lilly and Company $59.02 01/18/2024 Travel and Lodging Undisputed 01/23/2026 1135452607 CMS
Eli Lilly and Company $359.00 01/18/2024 Travel and Lodging Undisputed 01/23/2026 1135467228 CMS
Eli Lilly and Company $59.02 01/18/2024 Travel and Lodging Undisputed 01/23/2026 1135478386 CMS
Eli Lilly and Company $599.07 01/18/2024 Travel and Lodging Undisputed 01/23/2026 1135498904 CMS
Eli Lilly and Company $1,300.00 04/11/2024 Consulting Fee Undisputed 01/23/2026 1135492770 CMS
EMD Serono, Inc. $17.04 03/19/2024 Food and Beverage Undisputed 01/23/2026 1120222419 CMS
Gilead Sciences, Inc. $19.10 09/05/2024 Food and Beverage Undisputed 01/23/2026 1133835168 CMS
Lilly USA, LLC $3,250.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1135475202 CMS
Merck Sharp & Dohme LLC $29.41 08/27/2024 Food and Beverage Undisputed 01/23/2026 1141670022 CMS
Novartis Pharmaceuticals Corporation $4,875.00 01/10/2024 Consulting Fee Undisputed 01/23/2026 1087158777 CMS
Novartis Pharmaceuticals Corporation $19.96 06/11/2024 Food and Beverage Undisputed 01/23/2026 1087341247 CMS
Novartis Pharmaceuticals Corporation $28.46 06/13/2024 Food and Beverage Undisputed 01/23/2026 1087341245 CMS
Novartis Pharmaceuticals Corporation $28.71 07/08/2024 Food and Beverage Undisputed 01/23/2026 1087341237 CMS
Novartis Pharmaceuticals Corporation $19.78 09/11/2024 Food and Beverage Undisputed 01/23/2026 1087341253 CMS
Novartis Pharmaceuticals Corporation $13.72 12/17/2024 Food and Beverage Undisputed 01/23/2026 1087341267 CMS
PFIZER INC. $2,025.00 01/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1131448190 CMS
PFIZER INC. $77.09 05/31/2024 Food and Beverage Undisputed 01/23/2026 1131497546 CMS
PFIZER INC. $2,400.00 06/18/2024 Consulting Fee Undisputed 01/23/2026 1131537995 CMS
PFIZER INC. $62.07 09/13/2024 Food and Beverage Undisputed 01/23/2026 1131592668 CMS
PFIZER INC. $1,800.00 10/01/2024 Consulting Fee Undisputed 01/23/2026 1131517124 CMS
SpringWorks Therapeutics, Inc. $17.96 10/03/2024 Food and Beverage Undisputed 01/23/2026 1085808375 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $15.20 08/16/2024 Food and Beverage Undisputed 01/23/2026 1152211067 CMS
Tempus AI, Inc $29.56 10/07/2024 Food and Beverage Undisputed 01/23/2026 1150175286 CMS
TerSera Therapeutics LLC $18.23 04/11/2024 Food and Beverage Undisputed 01/23/2026 1144719148 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.